Cristal Therapeutics announces a publication in Chemical Science on CliCr platform.

  • Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent
  • Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development
  • CliCr® can be partnered or licensed as a stand-alone technology
  • Cristal is actively seeking partners for CliCr® for a variety of applications

Maastricht, The Netherlands, 29 September 2020 – Cristal Therapeutics, a Dutch phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces publication in Chemical Science, the flagship journal of the Royal Society of Chemistry,  of an article on the development of TMTHSI as part of the CliCr® platform providing fast and versatile conjugation tools.

For the optimal performance of CriPec® nanomedicines, it is essential to be able to attach a broad range of small molecule active agents and large molecular entities, biologics, to CriPec® nanoparticles.

The published research1 reports the development of a convenient and versatile  fast-reacting molecular entity for gluing very different compounds in a strain-promoted azide-alkyne cycloaddition click reaction to the nanoparticles, as well as a collection of linkers to attach the widely varying active small molecules  and biologics. Next to the already demonstrated examples, many additional applications are foreseen such as the construction of antibody drug conjugates in aqueous environments with faster kinetics that is essential for these delicate constructs.

For more information visit the Cristal Therapeutics website.

Afdrukken